RNS Number : 1562C Renalytix PLC 08 June 2023 Renalytix plc ("Renalytix" or the "Company") Result of General Meeting LONDON and SALT LAKE CITY , June 8, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that at the General Meeting (" GM ") held earlier today all resolutions
RNS Number : 5700B Renalytix PLC 05 June 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9 LONDON and SALT LAKE CITY , June 5, 2023 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter
RNS Number : 5773A Renalytix PLC 25 May 2023 Renalytix plc ("Renalytix" or the "Company") Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes Model expected to accelerate deployment of
RNS Number : 1093A Renalytix PLC 22 May 2023 Renalytix plc ("Renalytix" or the "Company") Expansion of insurance coverage for KidneyIntelX TM LONDON and SALT LAKE CITY , May 22, 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX) reports the expansion of insurance coverage for KidneyIntelX with
RNS Number : 0238Z Renalytix PLC 11 May 2023 Renalytix plc ("Renalytix" or the "Company") Notice of General Meeting and Posting of Circular LONDON and SALT LAKE CITY , May 11, 2023 - Renalytix (NASDAQ: RNLX) (LSE: RENX) announces that a circular containing a notice convening a General
RNS Number : 6476W Renalytix PLC 19 April 2023 Renalytix plc ("Renalytix" or the "Company") New Published Real-World Evidence Shows KidneyIntelX™ Utility Real-World Utility Data Demonstrates KidneyIntelX Optimizes Clinical Management in Early-Stage Chronic Kidney Disease Across Multiple
RNS Number : 8895V Renalytix PLC 12 April 2023 Renalytix plc ("Renalytix" or the "Company") Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting In a clinical decision effectiveness study, KidneyIntelX
RNS Number : 7000U Renalytix PLC 30 March 2023 Renalytix plc ("Renalytix" or the "Company") Half Year Report LONDON and SALT LAKE CITY , March 30, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), reports its financial results for the six months ended December 31, 2022.
RNS Number : 3435U Renalytix PLC 27 March 2023 The following amendment has been made to the 'Business Update' announcement released today, 27 March 2023 at 0700 under RNS No 2296U. The real-world evidence data published in the Journal of Primary Care Community Health was published in
RNS Number : 2296U Renalytix PLC 27 March 2023 Renalytix plc ("Renalytix" or the "Company") Business Update LONDON and SALT LAKE CITY , March 27, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) provides the following business update. Renalytix has further expanded its insurance coverage
